Development of Dissolving Microneedles Containing Finasteride With Improved Permeability and Bioavailability

The study developed dissolving microneedles (DMNs) containing finasteride (FNS) to improve drug permeability and bioavailability for androgenetic alopecia (AGA) treatment. The DMNs were designed to penetrate the stratum corneum, enhancing transdermal delivery and reducing systemic side effects associated with oral FNS. Fabricated using a solvent casting method, the DMNs demonstrated a uniform morphology and effective mechanical properties, achieving over 90% penetration through parafilm layers. In vitro and ex vivo studies showed that DMNs had faster release rates and higher transdermal permeation efficiency compared to traditional films, indicating their potential to enhance topical drug delivery for AGA. Future research will focus on evaluating the therapeutic efficacy of DMNs in promoting hair growth.